RxDoctor Payments Data

Vamshidhar Guduguntla, MD

Cardiovascular Disease · Roseville, MINPI 1174525729

Payments from drug & device makers

$1,852in general payments, 2019–2025

Across 69 payments — averaging $26.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$409
  • Boston Scientific$254
  • Abbott$243
  • Johnson & Johnson$194
  • Corcym Inc$166
  • E.r. Squibb & Sons, L.L.C.$136
  • plus $449 from 17 others

What the payments were for

  • Food & beverage$1,852100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,852 in reported general payments places this provider in the 40th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$129,717
Medicare patients
885
Services billed
2,429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban448$471,966
EntrestoSacubitril/Valsartan79$80,619
XareltoRivaroxaban35$49,834
JardianceEmpagliflozin28$29,726
Repatha SureclickEvolocumab39$28,347
MultaqDronedarone Hcl19$25,245
BrilintaTicagrelor34$25,062
Metoprolol Succinate578$11,561
Praluent PenAlirocumab11$5,204
Isosorbide Dinitrate45$4,690
Amiodarone Hcl100$4,429
ClopidogrelClopidogrel Bisulfate237$4,369
Diltiazem 24hr Er (Cd)Diltiazem Hcl106$4,364
Rosuvastatin Calcium270$4,227
Carvedilol301$3,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$67$80,61979 claims
Johnson & JohnsonXarelto$194$49,83435 claims
Boehringer IngelheimJardiance$39$29,72628 claims
Sanofi-aventis U.S. LLCMultaq$16$25,24519 claims
AstraZenecaBrilinta$12$25,06234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Roseville

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →